Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of TLL-018 in inadequately controlled moderate-to-severe chronic spontaneous urticaria
CTR20262928Phase 2Active
- Sponsor
- Highlight Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of girocitinib in chronic idiopathic urticaria (CIU), sponsored by Highlight Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
girocitinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20262928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262928.